Salivary gland carcinomas (SGC) account for less than 5% of head and neck malignant
neoplasms, further subcategorized in over 20 histological subtypes. For the most part …

Salivary gland cancers are rare with an annual incidence of approximately 3.0 cases per
100,000 in the United States accounting for less than 3% of all head and neck cancers. They …

Abstract Objective Mucoepidermoid Carcinoma (MEC) is the most common malignant
salivary gland neoplasm, representing 10 to 15% of all salivary neoplasms. A review of the …

Surgical resection remains the first line treatment for salivary gland cancer (SGC). In the
case of locally advanced disease, surgery is followed by adjuvant radiotherapy. Surgical …

Clinicopathological features, prognosis and therapeutic strategies for mucoepidermoid
carcinoma originating in salivary and salivary-type glands of the head and neck are …

Multiple 3-tiered grading systems exist for mucoepidermoid carcinoma (MEC), leading to
controversial results on the frequency and prognostic values of each grade. We aimed to …

Pulmonary mucoepidermoid carcinoma is an uncommon but distinctive manifestation of
mucoepidermoid carcinoma. Pulmonary mucoepidermoid carcinoma occurs in adults and …

Salivary gland cancer (SGC) is a rare malignancy consisting of 22 subtypes with different
genetic, histological and clinical characteristics. This rarity and heterogeneity makes …

Mucoepidermoid carcinoma (MEC) is generally characterized by an admixture of mucous,
epidermoid and intermediate type cells. Numerous variants morphologies are described and …

Background We sought to identify genomic alterations (GAs) in salivary mucoepidermoid
carcinomas. Patients and methods DNA was extracted from 48 mucoepidermoid …